Loading clinical trials...
Loading clinical trials...
A study of renal blood flow and renal oxygenation measured by magnetic resonance after a standardized fluid challenge in critically ill, resuscitated, patients with sepsis due to COVID-19 or other agents.
Critically ill, septic patients with or without acute kidney injury (AKI) above 18 years of age who have been circulatory and respiratory stabilized will be screened for inclusion. After the patients have been adequately treated with antimicrobial agents, source control and circulatory and respiratory stabilized, the patient will be moved to the Magnetic resonance imaging (MRI)-suite and placed in the MRI-camera. We plan to, at the same time, study renal blood flow (RBF) and oxygenation with 4 different MRI techniques; arterial spin labeling (ASL), Blood oxygen level dependent (BOLD)-technique, T(2) -Relaxation-Under-Spin-Tagging (TRUST) and Phase contrast at two conditions; 1. at baseline after stabilization 2. after intravenous infusion of 7,5 ml/kg mL Ringer's acetate The following data will be registered: 1. Age, gender, length and weight, 2. concomitant diseases and treatment, 3. present disease and treatment, 4. source of admission - emergency department or ordinary ward, 5. daily laboratory reports, 6. results from other investigations, e.g. x-rays, cultures etc., 7. recordings from the intensive care unit (ICU) monitors 8. Continuous renal replacement therapy (CRRT) - duration type, flow rate, replacement fluid, etc. 9. dead or alive at discharge and 90 days mortality, 10. renal function at discharge, 11. treatment restrictions, 12. if the patient has died, the results from a possible postmortem examination. As well as all data obtained during the MRI-examination.
Age
18 - No limit years
Sex
ALL
Healthy Volunteers
No
Uppsala University Hospital
Uppsala, Sweden
Start Date
December 7, 2016
Primary Completion Date
May 10, 2021
Completion Date
August 10, 2021
Last Updated
December 6, 2021
22
ACTUAL participants
Plasma expansion with Ringer's Acetate
OTHER
Lead Sponsor
Uppsala University
NCT05806645
NCT06082518
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and ConditionsNCT04850456